Acorda Therapeutics (ACOR) Tops Q3 EPS by 13c

Acorda Therapeutics (NASDAQ: ACOR) reported Q3 EPS of ($1.43), $0.13 better than the analyst estimate of ($1.56). Revenue for the quarter came in at $31.45 million versus the consensus estimate of $30.57 million.

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

You May Also Be Interested In

• Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
• Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance
• DouYu International Holdings Ltd (DOYU) Tops Q2 EPS by 67c